Based on the low prevalence of p19INK4d alterations in cancer and on the functional evidence we could conclude that the role of p19INK4d might be context-dependent and could play a role in resistance to genotoxic treatment and to CDK4/6-inhibitors. The gene discussed is CDKN2D; the disease is cancer.